NCT06648733 Improving Pharmacological Transition of Palliative Care Patients From Inpatient to Outpatient Care
| NCT ID | NCT06648733 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Muenster |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-06-20 |
| Primary Completion | 2025-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2024-06-20 with a primary completion date of 2025-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The transition of palliative care patients from inpatient to outpatient care is aimed to be improved through structured pharmaceutical discharge management by a trained pharmacist. This data will be compared with retrospective cases.
Eligibility Criteria
Inclusion Criteria: All individual indications for general and specialised palliative care as part of routine clinical practice (e.g.): * advanced, malignant tumour disease * advanced, chronic obstructive pulmonary disease * Patients with advanced disease and limited life expectancy (approx. 12 months) Further care in the SOPC Muenster (prospective data) Sufficient understanding of the German language to be able to understand the information and consent form Exclusion Criteria: Impossibility of understanding the information and declaration of consent.
Contact & Investigator
Christoph Klaas, Dr. rer. nat.
STUDY CHAIR
Pharmacy of the University Hospital Muenster
Frequently Asked Questions
Who can join the NCT06648733 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06648733 currently recruiting?
Yes, NCT06648733 is actively recruiting participants. Contact the research team at christoph.klaas@ukmuenster.de for enrollment information.
Where is the NCT06648733 trial being conducted?
This trial is being conducted at Münster, Germany.
Who is sponsoring the NCT06648733 clinical trial?
NCT06648733 is sponsored by University Hospital Muenster. The principal investigator is Christoph Klaas, Dr. rer. nat. at Pharmacy of the University Hospital Muenster. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.